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Abstract
CD33 is a Siglec (sialic acid- binding immunoglobulin- type lectin) receptor on mi-
croglia. Human CD33 can be alternatively spliced into two isoforms: the long iso-
form (CD33M) and a shorter isoform (CD33m) that lacks the sialic acid- binding site. 
CD33m appears to protect against Alzheimer's disease; however, it remains unclear 
how. To investigate potential mechanisms by which CD33m may confer protection, 
we expressed the CD33m and CD33M isoforms of human CD33 in mouse BV- 2 and 
human CHME3 microglial cells and assessed microglia functions. In the BV- 2 cells, 
CD33M inhibited microglial phagocytosis of beads, synapses, debris and dead cells, 
while CD33m increased phagocytosis of beads, debris and cells. RNAi knockdown of 
the endogenous mouse CD33 increased phagocytosis and prevented CD33m's (but 
not CD33M’s) effect on phagocytosis. CD33M increased cell attachment but inhib-
ited cell proliferation, while CD33m did the opposite. We also found that CD33M 
inhibited cell migration. In human CHME3 cells, CD33M increased cell attachment, 
but inhibited phagocytosis, proliferation and migration, whereas CD33m did the op-
posite. We conclude that CD33M inhibits microglial phagocytosis, inhibits migration 
and increases adhesion, while CD33m increases phagocytosis, proliferation and in-
hibits adhesion. Thus, CD33m might protect against Alzheimer's disease by increas-
ing microglial proliferation, movement and phagocytosis of debris and dead cells.
K E Y W O R D S
Alzheimer's disease, CD33, Microglia, Neuroinflammation, Siglec- 3
298  |     ANN BUTLER ET AL.
1  | INTRODUC TION
Microglia are brain- resident macrophages and can phagocytose 
pathogens, debris, protein aggregates, apoptotic cells, neurons 
and synapses (Galloway et al., 2019; Vilalta & Brown, 2018; Wolf 
et al., 2017). Microglial phagocytosis is mediated and regulated by 
several different receptors, including CD33. Human CD33 (also 
known as Siglec- 3) is a transmembrane receptor with an extracellular 
domain that binds sialic acid residues of glycoproteins on the cell sur-
face, and uses an intracellular ITIM (immunoreceptor tyrosine- based 
inhibition motif) domain and ITIM- like domain to inhibit immune/
inflammatory functions of cells (Estus et al., 2019; Paul et al., 2000). 
CD33 is expressed on myeloid cells, including microglia, monocytes, 
dendritic cells and peripheral macrophages (Crocker & Varki, 2001). 
In such cells, extracellular cross- linking using antibodies induces ty-
rosine phosphorylation of the ITIM and ITIM- like domains of CD33, 
which in turn recruits and activates the tyrosine phosphatases 
SHP- 1 and SHP- 2, resulting in inhibition of tyrosine phosphorylation 
signalling in the cells (Paul et al., 2000; Taylor et al., 1999; Ulyanova 
et al., 1999).
Human CD33 and mouse CD33 are homologous in their extra-
cellular domains, but have limited homology in their intracellular 
domains, such that mouse CD33 has an ITIM- like domain, but lacks 
the ITIM domain present on human CD33 (Brinkman- Van der Linden 
et al., 2003). Griciuc et al. (2013) reported that both human and 
mouse CD33 inhibited phagocytosis of amyloid beta (Aβ). Whereas 
Bhattacherjee et al. (2019) reported that expression of human CD33 
inhibited monocyte and microglial phagocytosis (of beads, dextran, 
myelin and Aβ), but expression of mouse CD33 had no effect on 
phagocytosis. These results appear inconsistent, so it remains un-
clear whether mouse CD33 has a similar function to human CD33.
Human CD33 can be alternatively spliced into two major iso-
forms known as CD33M (also known as FL- CD33), which encodes 
the full- length protein (containing all seven exons), whereas CD33m 
(also known as D2- CD33 or CD33ΔV- Ig), the shorter form, lacks the 
sialic acid- binding domain coded by exon 2 (Hernández- Case lles 
et al., 2006). Mouse CD33 can also be alternatively spliced into 
two isoforms but this occurs in the cytoplasmic region and there-
fore the isoforms are distinct from those in human CD33 (Tchilian 
et al., 1994). GWAS studies have identified a single- nucleotide poly-
morphism (SNP, rs3865444A) with decreased risk of Alzheimer's 
disease (AD) (Bradshaw et al., 2013; Hollingworth et al., 2011; 
Malik et al., 2013; Naj et al., 2011). Subsequently it was found that 
rs3865444 (in the promotor of CD33) is in linkage equilibrium with 
rs12459419 (which is located in the intron close to the start of exon 
2 of CD33), and this may be the disease- modifying site by increasing 
the splicing out of exon 2, thus decreasing the ratio of CD33M to 
CD33m (Estus et al., 2019). However, the underlying biology of why 
CD33m and CD33M confer differing susceptibility to developing 
Alzheimer's disease remains unclear.
One hypothesis is that CD33M inhibits microglial uptake of 
Aβ, while CD33m is non- functional and therefore does not inhibit 
phagocytosis of Aβ, resulting in increased Aβ uptake, reduced 
amyloid plaque load and disease (Bradshaw et al., 2013; Griciuc 
et al., 2013). Griciuc et al. (2013) found increased microglial expres-
sion of CD33M in Alzheimer's brains, and a positive correlation be-
tween microglial expression of CD33M and plaque load, suggesting 
that CD33M inhibits microglial phagocytosis of plaques. Consistent 
with this, CD33 knockout mice crossed with an amyloid model (APP/
PS1) had reduced plaque load. Furthermore, Griciuc et al. (2013) 
showed that microglia from CD33 knockout mice took up more Aβ, 
indicating that endogenous mouse CD33 inhibited microglial uptake 
of Aβ. They also reported that over- expression of human CD33M 
in BV- 2 microglial decreased Aβ uptake, while expression of human 
CD33m had no effect on Aβ uptake (Griciuc et al., 2013).
Bradshaw et al., (2013) compared humans with the risk and pro-
tective alleles of CD33, and found that the risk allele for AD was 
associated with: increased surface expression of CD33M on mono-
cytes, decreased Aβ uptake by monocytes and increased fibrillar 
Aβ in both live brain and post- mortem brains. The post- mortem 
brains had increased neuritic pathology and activated microglia 
(Bradshaw et al., 2013). Overall, these findings and those of Griciuc 
et al. (2013) are consistent with the hypothesis that the protective 
allele increases expression of CD33m relative to CD33M, and that 
CD33M inhibits microglial phagocytosis of Aβ, while CD33m is non- 
functional, potentially explaining why CD33M expression is detri-
mental in AD, whereas CD33m is protective.
The above model assumes that CD33m has lost function com-
pared to CD33M. However, recently a variant of the CD33 gene was 
found resulting in no CD33 expression and no change in AD risk. 
This finding is not consistent with CD33m being protective simply 
by loss of CD33M function, and therefore suggests the possibility 
that CD33m might gain some unknown function relative to CD33M 
to protect against AD (Estus et al., 2019; Papageorgiou et al., 2019).
Here, we sought to elucidate the roles of CD33 in microglial 
function and AD by determining: (1) whether CD33M and CD33m 
have differential effects on microglial phagocytosis of a variety of 
different phagocytic targets, including different forms of Aβ, (2) 
whether CD33 variants affect microglial migration, attachment and 
proliferation, (3) whether CD33m has a loss- of- function or gain- of- 
function effect on microglia, (4) whether mouse and human CD33 
have different effects on microglia functions, and finally (5) whether 
human CD33 has different effects on mouse and human cells. To 
address these aims, we expressed human CD33M and CD33m in 
mouse and human microglial cell lines (BV- 2 and CHME3 respec-
tively) and measured microglial functions, such as phagocytosis, mi-
gration, attachment and proliferation.
2  | MATERIAL S AND METHODS
2.1 | Ethical statement
Explicit institutional ethical approval was not required for this 
study. The ARRIVE guidelines were not applied since no animals are 
involved.
     |  299ANN BUTLER ET AL.
2.2 | Study design
This study was not pre- registered and no randomisation, blinding or 
sample calculation was performed. The study was exploratory and 
no exclusion criteria were pre- determined. For all experiments, un-
less stated otherwise, at least n = 3 independent cell culture prepa-
rations were used.
2.3 | Cell culture and lentiviral transfection for 
stable cell line generation
BV- 2 cells (RRID:CVCL_0182, ECACC) and CHME3 cells 
(RRID:CVCL_II76, a gift from Dr Svetlana Khoronenkova, who 
got them from Dr Brian Bigger, who got them from the origina-
tor Prof Marc Tardieu) were cultured in DMEM (Life Technologies, 
41965039), supplemented with 10% heat- inactivated foetal bovine 
serum (FBS, Life Technologies, 10500064) and 1% penicillin/strep-
tomycin (Sigma, P4333). Cells were cultured in pre- coated, cell cul-
ture treated 75 cm2 (T75) flasks and the attaching population of the 
cells were used for all experiments. Maximum passage used for BV- 2 
and CHME3 lines was 25.
For lentivirus generation packaging, psPAX2, and envelope, 
psMD2.G, plasmids were a gift from David Allendorf, University 
of Cambridge. The CD33m, CD33M and CD33- K7R transfer plas-
mids were a gift from Dr Roland Walter of Fred Hutchinson labo-
ratory, Seattle. EGFP only (control) transfer plasmid was sourced 
from Addgene (RRID:Addgene_12254). All three plasmids were 
combined according to Addgene lentiviral production protocol 
and transfected into HEK 293 (RRID:CVCL_0045, ECACC) cells 
using polyethylenimine (PEI, Sigma, 408727) transfection re-
agent. HEK 293 cells were cultured in DMEM/F12 with GlutaMAX 
media (Life Technologies, 31331093), supplemented with 10% 
heat- inactivated FBS and 1% penicillin/streptomycin. Maximum 
passage for HEK 293 used was 25. After 24 hr, media were ex-
changed. After a further 24 hr, media were harvested, centrifuged 
and filtered through a 0.45- micron filter. These media (containing 
lentiviral particles) were then added to BV- 2 cells at 50%– 60% 
confluency with the addition of 8 µg/mL polybrene (Merck, TR- 
1003- G). After 18 hr, cells were harvested and EGFP expression 
was assessed using flow cytometry (Accuri C6, BD systems). Cells 
that were positive for EGFP were FACS (Aria III) sorted collecting 
only the highest 25% of EGFP- expressing cells, and therefore the 
highest CD33M, CD33m or K7R- CD33 M expressing cells, for fu-
ture experiments.
For generation of human neuronal debris for CHME3 phagocy-
tosis experiments, human SH- SY5Y (RRID:CVCL_0019) cells were 
cultured in T75 flasks in DMEM/F12 with GlutaMAX media supple-
mented with 10% heat- inactivated FBS and 1% penicillin/streptomy-
cin. Maximum passage for SH- SY5Y cells was 25. None of the cell 
lines used are a commonly misidentified cell line; however, they have 
not been authenticated.
2.4 | RNAi knockdown of mouse CD33 M
Cells were seeded at 300,000 per well in six- well plate in DMEM 
supplemented with 10% heat- inactivated FBS and 1% penicillin/
streptomycin. After 24 hr, cells were subjected to RNAi:lipid mix 
containing 60 pmol CD33 targeting (Thermofisher, 4390771) or 
non- target (scrambled RNAi) (Thermofisher, 4390843) and 3% 
(v/v) lipofectamine 3000 (Thermofisher, L3000008) in serum- free 
opti- MEM media (Invitrogen, 51985). After 3- hr incubation at 37℃, 
transfection media were removed and replaced with DMEM sup-
plemented with 10% heat- inactivated FBS and 1% penicillin/strep-
tomycin. After a further 24 hr, cells were harvested using trypsin 
(Life Technologies, 15400054) and seeded into phagocytosis plates 
either 96- well or 24- well plates, assay depending, in DMEM sup-
plemented with 0.5% heat- inactivated FBS and 1% penicillin/strep-
tomycin. Phagocytosis assays were typically performed 24 hr later.
2.5 | RNA extraction and qPCR
Whole RNA was extracted using Monarch total RNA Miniprep kit 
(NEB, T2010). cDNA was synthesised using 1 µg of whole RNA, 
Superscript II Transcriptase kit (Invitrogen, 18064022) and ran-
dom hexamer primers (ThermoFisher, SO142). qPCR was per-
formed using SYBR Green JumpStart Taq ReadyMix (Sigma, 
S4438). Amplification was performed using Rotor- gene Q cy-
cler (Qiagen). Data were analysed using rotor- gene software and 
data expressed as comparative concentration which was normal-
ised to GAPDH house- keeping gene for BV- 2 cells or 18s rRNA 
for CHME3 cells. Primer sequences for human CD33 M (forward, 
TGGCTATGGATCCAAATTTCTGGCTG; reverse, AGCATAATGCAGC  
TCCTCATC) and human CD33m (forward, CCTGCTGTGGGCAGAC  
TTGAC; reverse, AGCATAATGCAGCTCCTCATC), human 18s rRNA 
(forward, GGCCCTGTAATTGGAATGAGTC; reverse, CCAAGATCCA  
ACTACGAGCTT), mouse GAPDH (forward, GTTGTCTCCTGCGACT  
TCA; reverse, GGTGGTCCAGGGTTTCTTA) and mouse CD33 M 
(forward, ATGAGAGAGCTGGTCCTGGT; reverse, CCCATGTGCACT  
GACAGCTT).
2.6 | Cell surface staining of mouse CD33 after 
RNAi knockdown
BV- 2 cells were harvested using trypsin and pelleted. BV- 2 cells were 
resuspended in flow cytometer staining solution (Invitrogen, 00- 4222- 
57). BV- 2 cells were then stained with either rat anti- IgG1 isotype 
control (RRID:AB_470047, ThermoFisher) or rat anti- mouse CD33 
(RRID:AB_2637179, ThermoFisher) both directly conjugated to phy-
coerythrin (PE) and diluted 1:50 (working concentration of 4 µg/ml) in 
staining solution at 4℃ for 30 min, to prevent receptor internalisation. 
All cells were washed with 1X PBS and phycoerythrin (PE) fluores-
cence quantified using flow cytometer (Accuri C6, BD systems).
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2.7 | Cell surface staining of human CD33 variants
Cells were harvested using trypsin and pelleted. Cells were re-
suspended in flow cytometer staining solution (Invitrogen, 00- 
4222- 57). For both BV- 2 and CHME- 3 CD33 over- expressing cell 
lines mouse anti- IgG1 isotype control (BioLegend, 400114) was 
used. For detection of human CD33M and K7R- CD33M mutant 
in both BV- 2 and CHME3s, mouse anti- human CD33 (clone h67.6) 
(RRID:AB_2566107, BioLegend) was used. Both the isotype con-
trol and anti- human CD33 (clone h67.6) antibodies were directly 
conjugated to phycoerythrin (PE) fluorophore and diluted 1:50 
(working concentration of 4 µg/ml) in staining solution at 4℃ 
for 30 min to prevent any receptor internalisation. For detec-
tion of CD33m, mouse anti- human CD33 (clone HIM3- 4) conju-
gated to phycoerythrin (PE) fluorophore (RRID:AB_10855031, 
Thermofisher Scientific) was diluted 1:50 (working concentration 
of 2 µg/ml) in staining solution and incubated at 4℃ for 30 min, 
to prevent receptor internalisation. All cells were washed with 
1X PBS and FL- 2 fluorescence quantified using a flow cytometer 
(Accuri C6, BD systems).
2.8 | Phagocytosis assays
For pH- Rodo (ThermoFisher Scientific, P36600) stained isolated 
synapses, neuronal debris and Alexa Fluor 555- labelled amyloid 
beta (Anaspec, ANA60480- 01). Cells were seeded in triplicate 
24 hr prior to target addition at 20,000 cells per well in DMEM 
supplemented with 0.5% heat- inactivated FBS and 1% penicillin/
streptomycin. Preparation of monomeric, oligomeric and fibrillar 
amyloid beta was conducted as described previously (Neniskyte 
et al. 2011). Isolated synapses were prepared as described by 
Dunkley et al (2008). Neuronal debris were obtained by scrap-
ing cells from live neuronal– glial culture (85% neurons), cells 
were passed through a 0.4 × 13- mm needle 10 times, then fluo-
rescently labelled with TAMRA (Nomura et al., 2017). For uptake 
into mouse BV- 2 cells, we used rat neuronal debris because rat 
and mouse are genetically similar, and more neurons can be ob-
tained from rats (consistent with the 3Rs). Whereas for human 
CHME3 cells, we made neuronal debris from human SH- SY5Y cells 
(RRID:CVCL_0019). SH- SY5Y cells were cultured to confluency, 
then harvested using trypsin and resuspended in 1X PBS. Cells 
were passed through 0.4 × 13- mm needle 10 times, then fluores-
cently labelled with TAMRA. Protein concentration of both rat and 
human neuronal debris was determined using Pierce BCA assay 
(ThermoFisher Scientific, 23227).
For uptake of fluorescent sky blue five micron carboxylated 
beads (Spherotech, FP- 0570- 2) and pH- Rodo- labelled PC12 
(RRID:CVCL_0481, ECACC) cells were seeded, in duplicate, 
24 hr prior to target addition at 50,000 cells per well in DMEM 
supplemented with 0.5% heat- inactivated FBS and 1% penicillin/
streptomycin. For 0.005% w/v fluorescent sky blue five micron 
carboxylated beads and 300,000 live or dead pH- Rodo- labelled 
PC12 incubation time was 3 hr with BV- 2 cells. For 16 µg of iso-
lated synapses, 30 µg of rat neuronal debris and 2 µM of amyloid 
beta incubation time was 1 hr with BV- 2 cells. Finally, for 60 µg of 
human SH- SY5Y neuronal debris, incubation time was 3 hr with 
CHME3 cells.
After incubation, cells were washed once with 1X PBS to re-
move non- phagocytosed cargo and then harvested using trypsin, 
pelleted and finally resuspended in 1X PBS for flow cytometry 
(Accuri C6, BD systems). To check the contribution of phagocy-
tosis to apparent uptake, we inhibited phagocytosis with 10- µM 
cytochalasin D for 1 hr before adding phagocytic targets (Figures 
S3– S7).
2.9 | Sialidase treatment and assessment of 
desialylation
For cells treated with sialidase enzyme, 5% exogenous neurami-
nidase enzyme (Sigma, N3001- 4UN) was added to cells for 1 hr 
before adding phagocytic target. To assess extent of desialyla-
tion BV- 2 cells were stained with FITC- conjugated peanut agglu-
tinin (PNA), which binds to the penultimate sugars of desialylated 
glycans (galactose followed by N- acetylglucosamine residues). 
Sialylation blocks PNA binding and therefore increased binding 
indicates desialylation.
2.10 | Flow cytometry
For flow cytometry, an Accuri C6 flow cytometer was used (BD sys-
tems). At least 5,000 events were analysed for each treatment rep-
licate. FlowJo (version 10) was used for creating raw histograms and 
flow plots. Fc blocking antibodies were not used. Forward and side 
scatter was used to distinguish cells from unphagocytosed targets, 
i.e., beads, debris and synapses, by gating on cells in the forward and 
side scatter plots. Within this scatter gate, a fluorescence gate was 
set to identify cells that were over a threshold of fluorescence. For 
phagocytic targets, this fluorescence gate was set so that for cells 
incubated in the absence of any fluorescent targets (i.e. absence of 
fluorescent beads, debris, synapses, Aβ or targets cells), 99% of the 
cells were below this gated fluorescence and 1% were above this 
gate. So, for cells incubated in the presence of fluorescent targets, 
the % of cells with fluorescence greater than the gated fluorescence 
were used as the measure the % of cells that had phagocytosed the 
targets. For detection of GFP (green fluorescent protein), PE (phy-
coerythrin) and pH- rodo, a 488- nm excitation laser was used, and 
fluorescence emission was measured using the following channels/
detectors: FL- 1/FITC, FL- 2/PE, FL- 3/PerCP- A respectively. For de-
tection of sky blue fluorescent beads, a 640- nm excitation laser and 
FL- 4/APC- A detector were used. For quantification of CD33 protein 
on the surface of cells, forward and side scatter was used to identify 
cells, and the FL- 2/PE fluorescence of IgG control- PE treated cells 
was used to gate the fluorescence of anti- CD33- PE- treated cells.
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2.11 | Attachment/xCELLigence assay
For attachment assays, E- plates (ACEA biosciences, 00300600900) 
96- well plates were used. First, the plate was coated with 10 µg/ml 
human fibronectin (Sigma, F0895) for at least 1 hr at room tempera-
ture (18℃). The plate was then blocked with 3% BSA for 1 hr at room 
temperature (18℃). The plate was then washed three times with 1X 
PBS, followed by addition of cells (15,000 per well). Real- time cell 
impedance measurements were collected using xCELLigence soft-
ware (ACEA biosciences) for at least 4 hr.
2.12 | Migration assay
Cells were seeded at 20,000 per well in DMEM supplemented with 
0.5% heat- inactivated FBS and 1% penicillin/streptomycin in the top 
compartment of trans- well apparatus (Coring, 3422). Cells were agi-
tated slowly for 2 min and then allowed to settle in incubator for at 
least 15 min before adding treatments to the bottom compartment. 
Treatments were as follows: 100 µM ATP and DMEM supplemented 
with 0.5% heat- inactivated FBS and 1% penicillin/streptomycin. 
DMEM supplemented with 0.5% FBS was used as a control so there 
would be no concentration gradient between the top and bottom 
compartment of the trans- well. BV- 2 cells were incubated for 2 hr, 
while CHME3 cells were incubated for 6 hr, both at 37℃, 5% CO2. 
Cells were fixed with 4% paraformaldehyde (PFA) and stained with 
4′,6- diamidino- 2- phenylindole (DAPI), then imaged using an EVOS mi-
croscope system (Thermofisher). The number of cells present on the 
bottom of the membrane (and therefore had migrated through the 
trans- well) was determined by the number of DAPI- positive nuclei.
2.13 | Proliferation assays
For both BV- 2 and CHME3s, cells were seeded at 100,000 per ml 
(final volume of 10 ml) in a T- 75 flask and cultured in DMEM sup-
plemented with 10% heat- inactivated FBS and 1% penicillin/strepto-
mycin for 48 hr. Cells were then harvested with trypsin and counted 
using a haemocytometer. To ensure BV- 2 cells were not proliferat-
ing during the 24- hr period between seeding and phagocytosis as-
says, cells were plated at 100,000 per ml in 24- well plate in DMEM 
supplemented with 0.5% heat- inactivated FBS and 1% penicillin/
streptomycin for 24 hr. They were then harvested with trypsin and 
counted using a haemocytometer.
2.14 | Immunohistochemistry
For Ki- 67 immunofluorescence, cells were plated at 100,000 per ml 
on coverslips in DMEM supplemented with 0.5% heat- inactivated 
FBS and 1% penicillin/streptomycin. After 24 hr, cells were washed 
with 1X PBS, fixed with 4% paraformaldehyde (PFA) for 15 min, 
permeabilised with 0.1% Triton- X:PBS for 5 min and then blocked 
in 3% BSA for at least 1 hr. After blocking, anti- Ki- 67 antibody 
(RRID:AB_2142366, Millipore) was added at 1:50 dilution (working 
concentration of 2 µg/ml) in 3% BSA overnight at 4℃ in a humidifying 
chamber. Then, cells were washed with 1X PBS three times, followed 
by incubation of secondary antibody (RRID:AB_2556776, Invitrogen) 
diluted 1:1,000 in 3% BSA for 1 hr at room temperature (18℃). Finally, 
cells were washed with 1X PBS three times, mounted on slides using 
mounting medium (containing 4′,6- diamidino- 2- phenylindole, DAPI) 
(Vector Laboratories, H- 1200) and imaged using epifluorescence mi-
croscope (Leica, DM16000 CS).
2.15 | Statistical analysis
The statistical analysis was performed on GraphPad prism (version 
8.0) data shown represented as a mean of at least n = 3 independ-
ent cell cultures preparations ± SEM. Shapiro– Wilk test of normality 
was performed; however, no outlier tests were performedThe usage 
“Shapiro– Wilk test normality test” has been changed to “Shapiro– 
Wilk test of normality”. Please check.. Statistical significance was 
assessed by repeated measures one- way ANOVA followed by 
Dunnett's or Tukey's post hoc test or paired Student's t test, unless 
stated otherwise. p ≤ .05 were considered significant.
3  | RESULTS
3.1 | CD33M inhibits, whilst CD33m increases 
phagocytosis of diverse targets by BV- 2 cells
We stably expressed variants of human CD33 in the mouse mi-
croglial BV- 2 cells using lentivirus vectors expressing either: (1) 
enhanced green fluorescent protein (EGFP) as control, (2) human, 
full- length CD33 (CD33M), (3) human, exon 2 lacking CD33 
(CD33m) or (4) the K7R variant of human, full- length CD33 (K7R- 
CD33M). The K7R variant cannot be ubiquitinated and thus has 
higher protein expression (Walter et al., 2007). We confirmed ex-
pression of the intended mRNA transcripts and CD33 protein on 
the plasma membrane (Figure S1 and S2). We then tested whether 
expression of the CD33 variants affected microglial phagocyto-
sis of various targets: (1) carboxylated five micron beads, which 
mimic the size and charge of cells, (2) neuronal debris, prepared by 
disruption of a neuronal culture, (3) isolated synapses, prepared 
as synaptosomes from rat brains, (4) live PC12 cells, a neuroen-
docrine cell line and (5) dead PC12 cells, killed with 2- µM stauro-
sporine. For all five phagocytic targets, there were similar trends: 
CD33M and K7R- CD33M expression inhibited phagocytosis, 
whereas CD33m expression increased phagocytosis, relative to 
the control transfection, although some changes were not sig-
nificant (Figure 1). Representative raw flow plots can be seen in 
Figures S3– S7. Microglial phagocytosis expressed as the mean % 
of cells phagocytosing these targets ± SEM were for beads: con-
trol 30 ± 3, CD33M 26 ± 2, CD33m 36 ± 4, K7R- CD33M 23 ± 3, 
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F I G U R E  1   CD33M decreases and CD33m increases microglial phagocytosis of beads, debris, synapses and cells. Phagocytosis by 
CD33M/m- expressing BV- 2 cell lines of: (a) carboxylated beads, (b) neuronal debris, (c) isolated synapses, (d) live PC12 cells and (e) dead 
PC12 cells. For all experiments, n = 4– 6 independent cell culture preparations. Repeats done on the same day with the four variant cell lines 




































































































































































F I G U R E  2   Knockdown of mouse CD33 and/or sialidase increases microglial phagocytosis. Phagocytosis by BV- 2 cells treated ± sialidase 
with non- targeting control RNAi or CD33 RNAi of: (a) five micron beads, (b) neuronal debris, (c) isolated synapses and (d) live PC12 cells. For 
all experiments n = 3– 5 independent cell culture preparations. Repeats done on the same day with the four variant cell lines are linked by solid 






















































































































































































     |  303ANN BUTLER ET AL.
(Figure 1a), for neuronal debris: control 30 ± 6, CD33M 26 ± 6, 
CD33m 4.5 ± 4, K7R- CD33M 19 ± 4 (Figure 1b), for isolated syn-
apses: control 24 ± 5, CD33M 20 ± 4, CD33m 27 ± 4, K7R- CD33M 
16 ± 4 (Figure 1c), for live PC12 cells: control 12 ± 1, CD33M 9 ± 1, 
CD33m 16 ± 3, K7R- CD33M 6 ± 1 (Figure 1d) and for dead PC12 
cells: control 24 ± 3, CD33M 19 ± 3, CD33m 31 ± 3, K7R- CD33M 
17 ± 2 (Figure 1e). Thus, CD33M inhibits phagocytosis and CD33m 
increases phagocytosis.
3.2 | Knockdown of endogenous mouse CD33 or 
desialylation of cells increases phagocytosis by  
BV- 2 cells
As expression of human CD33M in mouse BV- 2 cells inhibited phago-
cytosis, we tested whether knockdown of the endogenous mouse 
CD33 would increase phagocytosis, as the role of mouse CD33 
remains unclear. We confirmed that the RNAi directed to mouse 
CD33 reduced CD33 protein expression at the plasma membrane by 
50%– 60% (Figure S8b & c). RNAi knockdown of endogenous mouse 
CD33 increased microglial phagocytosis of all targets. Results are 
expressed as mean % of cells phagocytosing targets ± SEM: beads 
(control RNAi 13 ± 1, CD33 RNAi 20 ± 2, Figure 2a), neuronal debris 
(control RNAi, 17 ± 2, CD33 RNAi 25 ± 2, Figure 2b), synapses (con-
trol RNAi 9 ± 2, CD33 RNAi 13 ± 2, Figure 2c), live PC12 cells (con-
trol RNAi 15 ± 2, CD33 RNAi 17 ± 2, Figure 2d) and dead PC12 cells 
(control RNAi 21 ± 8, CD33 RNAi 30 ± 9, Figure 2e). Note that CD33 
knockdown and desialylation did not significantly affect uptake of 
live cells. These data indicate that endogenous mouse CD33 inhibits 
microglial phagocytosis similarly to human CD33M.
Because CD33 is a sialic acid- binding receptor potentially reg-
ulated by sialylation of the cell surface (Brinkman- Van der Linden 
et al., 2003), we tested whether desialylation of the cells affected 
phagocytosis via CD33. We desialylated the microglia by pre- 
incubation with sialidase for 1 hr, and verified effective desialyla-
tion by assaying the binding of peanut agglutinin (PNA), which binds 
galactose residues only after the removal of terminal sialic acid 
residues that block PNA binding (Figure S8d). Desialylation of the 
microglia increased phagocytosis of beads. All results are expressed 
as mean % of cells phagocytosing targets ± SEM: control no sialidase 
13 ± 1, after sialidase treatment to 19 ± 1 (Figure 2a), but decreased 
phagocytosis of synapses: control no sialidase 9 ± 2, after sialidase 
treatment 7 ± 2 (Figure 2c). Desialylation also increased phagocy-
tosis of neuronal debris and cells, but these changes were not sig-
nificant (Figure 2b, d & e). Knockdown of mouse CD33 prevented 
the effect of desialylation on phagocytosis of beads (CD33 no si-
alidase 20 ± 2, after sialidase treatment to 24 ± 2, Figure 2a) and 
synapses (CD33 no sialidase 13 ± 3, after sialidase treatment 10 ± 2, 
Figure 2c). This suggests that the effect of desialylation on phago-
cytosis could be partly mediated via CD33. However, desialylation 
still increased phagocytosis of beads and decreased phagocytosis 
of synapses after CD33 knockdown, so desialylation appears to in-
crease phagocytosis at least partly by CD33- independent means.
3.3 | Knockdown of endogenous mouse CD33 
prevents human CD33m increasing phagocytosis in 
BV- 2 cells
One possible means by which human CD33m expression might in-
crease phagocytosis is by disrupting the function of endogenous 
mouse CD33 (e.g. by dimerising with it). To test this possibility, we 
compared the effect of human CD33 expression on phagocytosis 
in the presence or absence of endogenous mouse CD33 knock-
down using RNAi. We chose to examine the effect of knockdown 
and expression on phagocytosis of neuronal debris as this may be 
the most physiological relevant target of phagocytosis, and had a 
robust response to CD33 expression (Figure 1b). As expected, in 
BV- 2 cells treated with a control, non- targeting RNAi, CD33M and 
K7R- CD33M reduced phagocytosis, and CD33m increased phagocy-
tosis. Phagocytosis is expressed as mean % of cells phagocytosing 
debris ± SEM were: control 12 ± 2, CD33M 8 ± 1, CD33m 18 ± 2, 
K7R- CD33M 6 ± 1 (Figure 3a). However, in cells treated with RNAi 
to knockdown endogenous mouse CD33, CD33m did not change 
phagocytosis, while CD33M and K7R- CD33M still reduced phago-
cytosis: control 28 ± 5, CD33M 18 ± 3, CD33m 29 ± 5, K7R- CD33M 
11 ± 1 (Figure 3b). This is consistent with human CD33m increasing 
phagocytosis by disrupting the function of endogenous mouse CD33.
3.4 | CD33m increases monomeric Aβ uptake, and 
CD33M inhibits fibrillar Aβ uptake by BV- 2 cells
CD33M has previously been shown to inhibit microglial uptake of 
Aβ, but the form of Aβ was undefined (Bradshaw et al., 2013; Griciuc 
et al., 2013). So, we tested the effect of the various human CD33 
F I G U R E  3   Knockdown of endogenous mouse CD33 prevents 
human CD33m increasing phagocytosis. (a) BV- 2 cells expressing 
human CD33 variants were subjected to either control/scrambled 
RNAi or (b) mouse CD33 targeting RNAi and percentage of 
phagocytosis of rat neuronal debris was quantified using flow 
cytometry. N = 6 independent cell culture preparations. Repeats 
done on the same day with the four variant cell lines are linked 
by solid lines. Statistics: repeated measures, one- way ANOVA. * 
is with respect to control (a) scrambled RNAi or (b) CD33 RNAi 
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variants on microglial uptake of monomeric, oligomeric and fibril-
lar A. CD33M and K7R- CD33M had a tendency to inhibit uptake of 
all forms of Aβ; however, only the inhibition of monomeric Aβ up-
take by CD33M was statistically significant (Figure 4). CD33m had 
a tendency to increase uptake of all forms of Aβ; however, only the 
increased uptake of monomeric Aβ by CD33m was statistically sig-
nificant (Figure 4). Results are expressed as mean % of cells phagocy-
tosing Aβ ± SEM. For monomeric Aβ: control 23 ± 8, CD33M 21 ± 8, 
CD33m 28 ± 9, K7R- CD33M 12 ± 4 (Figure 4a), for oligomeric Aβ: 
control 16 ± 5, CD33M 14 ± 5, CD33m 22 ± 7, K7R- CD33M 9 ± 4 
(Figure 4b) and for fibrillar Aβ: control 55 ± 12, CD33M 48 ± 12, 
CD33m 65 ± 10, K7R- CD33M 32 ± 12 (Figure 4c). Thus, there is a 
tendency for CD33M to decrease Aβ uptake, and for CD33m to in-
crease Aβ uptake, as seen with phagocytosis of all other phagocytic 
targets (Figure 1).
3.5 | K7R- CD33M increases cell attachment to 
fibronectin, whilst CD33m decreases attachment to 
fibronectin in BV- 2 cells
Microglial migration is in part determined by cellular adhesion to ex-
tracellular matrix, so we tested whether the CD33 variants affected 
microglial adhesion to fibronectin (which is a major component of 
brain extracellular matrix) measured by the increase in impedance 
as the cells adhere and spread on fibronectin- coated plates. K7R- 
CD33M increased adhesion to fibronectin (K7R- CD33M 194 ± 27% 
of control ± SEM, Figure 5), while CD33m reduced adhesion (CD33m 
51 ± 9% of control ± SEM, Figure 5). CD33m reduced cell spreading 
on the same matrix measured as the area of the plates occupied by 
the cells (Figure S9). Thus, CD33M over- expression appears to in-
crease matrix adhesion and CD33m reduces matrix adhesion.
3.6 | CD33M inhibits migration of BV- 2 cells 
towards ATP
Phagocytosis of targets normally requires migration to those tar-
gets, so we tested whether the CD33 variants affected microglial 
migration through a trans- well in response to a chemotactic gradient 
of ATP. ATP increased migration through the trans- well by control 
and CD33m- expressing microglia. Results expressed as cell num-
bers migrated ± SEM. (ATP control: 1,095 ± 179, ATP + CD33m: 
905 ± 135, Figure 6a), but did not significantly stimulate migration of 
cells expressing CD33M or K7R- CD33M (ATP + CD33M 568 ± 112, 
ATP + K7R- CD33M: 598 ± 133, Figure 6a). This indicates that 
CD33M inhibits microglial migration to ATP.
3.7 | CD33M reduces microglia proliferation, whilst 
CD33m increases proliferation in BV- 2 cells
Because cellular adhesion to substrate can affect proliferation 
(Lundell et al., 1996; Schwartz & Assoian, 2001), we tested whether 
the CD33 variants affected microglial proliferation, measured as 
cell numbers after 48 hr in 10% serum. CD33M and K7R- CD33M 
inhibited proliferation, while CD33m increased cell proliferation. 
Results expressed as cell numbers per mL ± SEM were: for con-
trol 813 ± 68, K7R- CD33M 513 ± 59, CD33M 607 ± 84, CD33m 
920 ± 61 (Figure 6b). Similarly, CD33M and K7R- CD33M inhibited 
cellular Ki- 67 immunostaining (a marker of cell proliferation), while 
CD33m increased Ki- 67 staining (Figure S10a).
Because the CD33 variants affected cell proliferation measured 
as cell numbers after 48 hr in 10% serum, we checked whether the 
CD33 variants affected cell numbers in the conditions used to assay 
phagocytosis by plating BV- 2 cells in DMEM supplemented with 
0.5% serum and counting cell numbers after 24 hr. We saw no differ-
ences in cell numbers between the different lines in these conditions 
(Figure S10b), indicating that any apparent differences in phagocyto-
sis between the variants were not owing to differences in cell number.
3.8 | CD33M decreases phagocytosis and 
proliferation but increases adhesion to fibronectin in 
human CHME3 cells
To test whether the effects of expressing human CD33 vari-
ants in mouse BV- 2 cells were also seen in human cells, we stably 
F I G U R E  4   K7R- CD33M inhibits microglial phagocytosis of Aβ. Phagocytosis by CD33M/m- expressing BV- 2 cells of: (a) monomeric Aβ, (b) 
oligomeric Aβ or (c) fibrillar Aβ. For all experiments n = 6 independent cell culture preparations. Repeats done on the same day with the four 
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expressed the same human CD33 variants in a human microglia cell 
line, CHME3 cells. CHME3 cells were derived by SV40- dependent 
immortalisation of human embryonic microglial cells, and are also 
known as HMC3 cells (Dello Russo et al., 2018).
We confirmed expression of the CD33 variants at the level of 
both mRNA and cell surface protein CHME3 after lentiviral transfec-
tion of the CHME3 cells (Figure S11 & S12).
To assess the effect of the isoforms on phagocytosis, we tested 
uptake of pH- rodo- labelled neuronal debris from human SH- SY5Y 
neuroblastoma cells. We found that expression of CD33M and K7R- 
CD33M inhibited phagocytosis, while CD33m increased phago-
cytosis of debris compared to control. Results expressed as mean 
% of cells phagocytosing debris ± SEM (control 22 ± 4, CD33M 
17 ± 3, CD33m 35 ± 3, K7R- CD33M 9 ± 2, Figure 7a). These 
findings are consistent with those seen in the BV- 2 cells (Figures 1b 
& 3a), i.e., CD33M increases phagocytosis, while CD33m decreases 
phagocytosis.
We assessed proliferation of CHME3 cells expressing the 
different CD33 variants by seeding the same cell numbers then 
counting cells 48 hr later. We found that expression of CD33M and 
K7R- CD33M decreased the proliferation rate, whereas expression 
of CD33m increased the proliferation rate compared to the con-
trol cells. Results expressed as cell number per mL ± SEM (con-
trol 290 ± 12, CD33M 225 ± 10, K7R- CD33M 140 ± 12, CD33m 
405 ± 17, Figure 7b). Again, these data are consistent with the 
findings seen in the BV- 2 cells (Figure 6b). Note that CHME3 cells 
proliferate at a slower rate than BV- 2 cells, and therefore the cell 
numbers were lower, but the same effect of CD33M decreasing 
F I G U R E  5   K7R- CD33M increases and CD33m decreases cell attachment to fibronectin. Attachment of human CD33 variant- expressing 
BV- 2 cells to fibronectin over 30 min, measured by electrical impedance of cell layer. n = 4 independent cell culture preparations. Statistics: 
two- way ANOVA. * is with respect to control cells. ***p <.001, ****p <.0001






























F I G U R E  6   CD33M decreases migration and cell proliferation, whereas CD33m increases cell proliferation. (a) Number of DAPI- 
positive nuclei (of ATP- induced migrated cells) present on bottom of trans- well membrane following 2- hr incubation. N = 6 independent 
cell culture preparations. Statistics: repeated measures one- way ANOVA. (b) Proliferation rate was measured as cell density (counted by 
haemocytometer) 48 hr after seeding the same density of cells in DMEM supplemented with 10% heat- inactivated FBS. N = 3 independent 
cell culture preparations. Repeats done on the same day with the four variant cell lines are linked by solid lines. Statistics: repeated measures 
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proliferation and CD33m increasing proliferation was found in the 
two cell lines.
To assess migration of CHME3 cells expressing the CD33 vari-
ants, we counted cells migrating through a trans- well in response to 
an ATP gradient, as previously for BV- 2 cells. CD33M had a tendency 
to decrease migration, and CD33m had a tendency to increase mi-
gration, but due to the variability of the control, the only significant 
difference was between CD33M and CD33m. Results expressed as 
mean % of migrated cells ± SEM were: control 2,485 ± 560, CD33M 
1,326 ± 123, CD33m 3,759 ± 434 and K7R- CD33M 1,086 ± 87 
(Figure 7c). These findings are consistent with those seen in BV- 2 
cells (Figure 6a), i.e. CD33m has the opposite effect to CD33M on 
migration.
Finally, to assess the effect of CD33 variants on cellular adhe-
sion, we measured the rate of adhesion to fibronectin- coated plates 
as before, but for a longer period of time (4 hr), as CHME3 cells took 
longer to adhere to surfaces than BV- 2 cells. Expression of CD33M 
and K7R- CD33M increased adhesion, whereas CD33m decreased 
adhesion. Results expressed as % of control at 4 hr ± SEM (control 
62 ± 12, CD33M 87 ± 15, K7R- CD33M 100 ± 19, Figure 7d). These 
results in CHME3 cells are consistent with the findings in BV- 2 cells 
(Figure 5), i.e., CD33M increases adhesion, while CD33m decreases 
adhesion. Overall, the effects of expressing CD33 variants in human 
CHME3 cells are similar to expressing the variants in mouse BV- 2 
cells.
4  | DISCUSSION
CD33 is an inhibitory receptor expressed on myeloid cells, includ-
ing microglia, potentially activated by sialic acid residues (Lajaunias 
et al., 2005). CD33m is thought to have a reduced function relative to 
CD33M, because of this splice variant lacking the sialic acid- binding 
domain (Griciuc et al., 2013; Siddiqui et al., 2017). Consistent with 
this, it was reported that CD33M inhibited microglial phagocytosis 
of Aβ, while CD33m had no effect. This could explain why expres-
sion of CD33m, rather than CD33M, apparently protects against AD, 
as it has lost the capacity to inhibit microglia phagocytosis (Griciuc 
et al., 2013; Siddiqui et al., 2017). However, we show that expres-
sion of CD33m actually increases microglial phagocytosis of multiple 
F I G U R E  7   In human CHME3 cells, CD33M decreases and CD33m increases microglial phagocytosis, migration and proliferation, but 
CD33M increases adhesion whereas CD33m decreases adhesion. (a) Phagocytosis of 60 µg of human SH- SY5Y neuronal debris by CHME3 
cells expressing CD33 variants. n = 5 independent cell culture preparations. Statistics: repeated measures one- way ANOVA. * is with respect 
to control cells, *p <.05, **p <.01. (b) Proliferation rate was measured as cell density (counted by haemocytometer) 48 hr after seeding 
the same density of cells in DMEM supplemented with 10% heat- inactivated FBS. N = 4 independent cell culture preparations. Statistics: 
repeated measures one- way ANOVA. * is with respect to control cells, *p <.05, **p <.01. (c) Migration was measured as the number of 
DAPI- positive cells present on bottom of the trans- well, 6 hr after adding cells above the trans- well and adding ATP below the trans- well. 
N = 3 independent cell culture preparations. Repeats done on the same day with the four variant cell lines are linked by solid lines. Statistics: 
repeated measures one- way ANOVA, * is with respect to CD33M cells, *p <.05. (d) Attachment of human CD33 variant- expressing CHME3 
cells to fibronectin over 240 min, measured by electrical impedance of cell layer. Statistics: two- way ANOVA. * is with respect to control 
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phagocytic targets (beads, debris and cells) compared to control. 
While expression of CD33M had the opposite effect, decreasing the 
phagocytosis of these targets, as well as synapses.
Estus et al., (2019) argued that CD33m may have a gain of func-
tion, because another CD33 variant that is effectively a knockout 
does not decrease risk of AD. A potential mechanism for such a gain 
of function could be that CD33m heterodimerises with CD33M to 
block its function potentially via the C2 domains of both isoforms 
(Estus et al., 2019). We find that expression of CD33m in the BV- 2 
cells increases microglial phagocytosis, but this effect is lost when 
endogenous mouse CD33 is knocked down, which itself increases 
phagocytosis. This suggests that human CD33m may have a dom-
inant negative effect over mouse CD33M, potentially by heterodi-
merising with it. However, CD33m also had the opposite effects to 
CD33M in human CHME3 that do not express endogenous CD33 
(Figures S11 and S12). Siddiqui et al. (2017) found endogenous 
expression of CD33M and CD33m in CHME5 cells, but it remains 
unclear how these cells are related to CHME3 cells (Dello Russo 
et al., 2018). As CD33m expression affected CHME3 functions in 
the absence of CD33M, CD33m may also have effects independent 
of CD33M. Possibilities might include: CD33m acting as an ITAM 
receptor (Estus et al., 2019), CD33m acting intracellularly (Siddiqui 
et al., 2017) or CD33m binding SHP- 1/2 without activating them and 
thereby inhibiting their activation. As we see a small proportion of 
CD33m present on the cell surface but a large expression of CD33m 
mRNA in both BV- 2 and CHME3 cells (Figures S1, S2, S11 and S12), 
it is feasible that CD33m is more highly expressed intracellularly, al-
though we have not tested this.
It could be argued that the various phagocytic targets we have 
used, including Aβ, beads, neuronal debris, isolated synapses and 
dead cells, are all forms of “debris”. It is generally thought that ex-
tracellular debris accumulates in the brain with neurodegenerative 
diseases (Takahashi et al., 2007; Neumann et al., 2008; Marquez- 
Ropero et al. 2020). Neurodegeneration may generate debris as 
dead neurons and bits of neurons, but such debris might also induce 
neurodegeneration, for example, by activating microglia (Map his 
et al., 2015; Spangenberg et al., 2016). Thus, one possible means 
by which CD33M may predispose to AD is by blocking microglial 
phagocytosis of the debris accumulating during neurodegeneration 
(or ageing), thereby exacerbating neuroinflammation.
TREM2 is one of the main phagocytic receptors mediating mi-
croglial phagocytosis of debris (Takahashi et al., 2005), and loss- of- 
function mutations in TREM2 predispose to AD (Sudom et al., 2018), 
and this might potentially be due to reduced microglial phagocytosis 
of debris. CD33 could potentially antagonise phagocytic signalling 
by TREM2 (or CR3), as TREM2 and CR3 activate phagocytosis via 
inducing phosphorylation of the tyrosine- protein kinase Syk, while 
CD33 activates the tyrosine- protein phosphatases SHP- 1 and 
SHP- 2 (Paul et al., 2000), which may dephosphorylate Syk and Syk 
substrates. This may be one potential mechanism by which CD33M 
is inhibiting phagocytosis in our study. Consistent with this, Griciuc 
et al. (2019) showed that in the 5XFAD mouse model of AD, TREM2 
knockout increased the pathology, while CD33 knockout reduced 
the pathology, but knocking out both TREM2 and CD33 resulted in 
the increased pathology of the TREM2 knockout, suggesting that 
TREM2 was acting “downstream” of CD33 to induce these effects. 
These results are consistent with CD33 simply suppressing TREM2 
signalling via activating SHP- 1/2 (as CD33 then requires TREM2 sig-
nalling to have an effect), but they do not rule out more complex 
interactions between CD33 and TREM2.
Mouse and human CD33 have homologous extracellular do-
mains, and divergent intracellular domains, but whether their func-
tions diverge is less clear. Bhattacherjee et al., (2019) found that 
expression of human CD33 inhibited phagocytosis, but expres-
sion of mouse CD33 did not inhibit phagocytosis (Bhattacherjee 
et al., 2019). However, Gricuic et al., (2013) found that knockout of 
CD33 increased microglial phagocytosis of amyloid beta, and this is 
consistent with our finding that RNAi knockdown of mouse CD33 in-
creased phagocytosis of beads, debris and synapses. These discrep-
ancies between groups could be because of different experimental 
techniques, cells, animals, levels of CD33 expression or levels of cell 
sialylation.
CD33 is thought to be an inhibitory receptor potentially activated 
by sialic acid residues of other glycoproteins (Lajaunias et al., 2005). 
We find that desialylation of microglia by adding sialidase increases 
phagocytosis of beads, consistent with previous findings (Allendorf 
et al., 2020; Nomura et al., 2017; Pluvinage et al., 2019), but de-
creased phagocytosis of synapses. RNAi knockdown of mouse CD33 
reduced the effect of desialylation on phagocytosis, suggesting that 
CD33 may contribute to this effect, but the data were not robust 
enough to make a firm conclusion. Recently, Pluvinage et al., (2019) 
showed that CD22 (Siglec- 2) was required for the effect of sialyla-
tion/desialylation on microglial phagocytosis (Pluvinage et al., 2019); 
and Allendorf et al. (2020) found that complement receptor 3 was 
also required (Allendorf et al., 2020). As different phagocytic re-
ceptors may be required for phagocytosis of beads and synapses, 
it seems reasonable that desialylation may affect these different re-
ceptors differently, resulting in increased phagocytosis of beads but 
decreased phagocytosis of synapses.
Microglial phagocytosis normally requires microglial migration, 
so we tested the effect of CD33 on migration of microglia through 
trans- wells in response to a chemotactic gradient of ATP. We found 
that expression of human CD33M in both cell types inhibited mi-
croglial migration towards ATP, whereas expression of CD33m did 
not inhibit migration. CD33M also increased microglial attachment 
to fibronectin in CHME3 cells but only with supraphysiological levels 
of CD33M (K7R- CD33M) in BV- 2 cells. Whereas CD33m reduced 
both attachment to fibronectin in both cell lines and cell spreading 
on fibronectin in the BV- 2 cells. Together, these findings suggest 
that over- expression of CD33M increases microglial attachment, 
which may reduce migration, and potentially reduce phagocytosis. 
Whereas CD33m decreases attachment, potentially causing in-
creased phagocytosis.
Increased adhesion has been linked to reduced migration in a 
number of cell types (DiMilla et al., 1991; Palecek et al., 1997; Schmidt 
& Friedl, 2010). Thus, it is possible that the increase in adhesion 
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induced by CD33M might contribute to reduced migration found in 
the presence of ATP. Other Siglecs have been shown to inhibit mi-
gration, including Siglec- E in inhibition of neutrophil and monocyte 
recruitment, and CD22 in inhibition of B cell migration and adhesion 
(McMillan et al., 2013; Nitschke et al., 1997). CD33 has been shown to 
mediate adhesion of CD33- expressing cells to erythrocytes via bind-
ing to sialic acid residues on the erythrocytes (Freeman et al., 1995). It 
could be that over- expression of CD33M increases cellular adhesion 
and spreading by binding sialic acid residues on fibronectin, but we 
do not think this is the case, as sialidase treatment of the fibronectin 
to remove sialic acid residues did not significantly decrease CD33M- 
induced adhesion in BV- 2 cells (data not shown).
Another feature of microglial activation is proliferation: microglia 
can proliferate in response to damage, pathogens or inflammation. 
We found that CD33M inhibits proliferation, whereas CD33m stim-
ulates proliferation in both cell lines. Increased proliferation in the 
presence of CD33m potentially means more microglia are present to 
clear debris and Aβ, and thereby potentially protecting the brain in 
AD. Cellular attachment can induce proliferation in some cell types 
(Pugacheva et al., 2006). A potential role of CD33 in proliferation has 
been shown as activation of CD33 by anti- CD33 antibodies reduced 
proliferation of leukaemic cells (Balaian et al., 2003; Vitale et al., 1999).
The microglial processes investigated in this study, prolifer-
ation, migration and phagocytosis, are all key aspects of microglia 
activation, and all are inhibited by CD33M. Microglia activation is 
a hallmark of neurodegenerative diseases such as AD. Our findings 
suggest a potential novel role of CD33m in increasing microglial 
proliferation, movement and phagocytosis of debris and Aβ, which 
might contribute to protecting the AD brain. However, further work 
is required to determine the molecular mechanisms by which CD33m 
and CD33M confer these differential effects on microglia.
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